Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37–144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five‐year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse.

中文翻译：

---

三年后，急性淋巴细胞白血病患者仍然有复发的风险。国际MRC UKALLXII / ECOG E2993试验的结果。

在急性淋巴细胞白血病（ALL）中，晚期复发[从完全缓解（CR）起> 3年]是罕见的。提供了来自MRC UKALLXII / ECOG E2993试验的数据，以评估成人ALL晚期复发的发生率和特征。在1,909例患者中，有1,752例（92％）达到了CR，其中757例（43·2％）复发。三年内达到691（91·3％），超出三年达到66（8·7％）。在这66例患者中，中位复发时间为47（37-144）个月。超过3年的复发率达到CR的人数占3·8％。在三年，五年和十年时，复发的累积风险分别为40％，43％和45％。在1752名获得CR的患者中，有11·7％接受了自体移植和40·6％的异体移植，而在CR1中。在自体患者中，有43·2％的患者早期复发，有3·4％的患者晚期复发。但是，在同种异体患者中，早期复发率为13·2％，晚期仅为1·3％。早期和晚期复发患者的五年复发总生存率分别为5·8％和20％。总之，成年ALL ALL的晚期复发并不罕见，与早期复发相比，复发后具有更好的预后。